Read by QxMD icon Read

Radiotherapy clinical trial

Jenny Capuccini, Gabriella Macchia, Eleonora Farina, Milly Buwenge, Domenico Genovesi, Luciana Caravatta, Nam P Nguyen, Silvia Cammelli, Savino Cilla, Tigeneh Wondemagegnhu, A F M Kamal Uddin, Mostafà Aziz Sumon, Francesco Cellini, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti
Metastases with soft tissues invasion, impending fractures or spinal cord compression (complicated bone metastases) represent a common clinical problem in advanced cancers and frequently lead to deterioration of patients' quality of life (QoL). A phase I-II study was planned to define the maximum tolerated dose (MTD) of a short-course radiotherapy (RT) and its efficacy in palliation of complicated bone metastases. A phase I trial was designed with three dose-escalation steps: 16, 18, and 20 Gy. Total dose at each level was delivered in 2 days, twice daily...
August 18, 2018: Clinical & Experimental Metastasis
Omar Abdel-Rahman
PURPOSE: To evaluate the impact of regional nodal irradiation (RNI) among N1 operable breast cancer patients who underwent adequate axillary dissection and received adjuvant chemotherapy. PATIENTS AND METHODS: This is a pooled analysis of 812 breast cancer patients referred for adjuvant systemic therapy in 2 prospective randomized studies: NCT00174655 (BIG 02/98) and NCT00312208 (BCIRG005). Overall survival was assessed according to whether patients received supraclavicular and/or internal mammary radiotherapy through Kaplan-Meier estimates...
July 24, 2018: Clinical Breast Cancer
Hayley M Reynolds, Bimal K Parameswaran, Mary E Finnegan, Diana Roettger, Eddie Lau, Tomas Kron, Mark Shaw, Sarat Chander, Shankar Siva
PURPOSE: To explore the utility of diffusion and perfusion changes in primary renal cell carcinoma (RCC) after stereotactic ablative body radiotherapy (SABR) as an early biomarker of treatment response, using diffusion weighted (DWI) and dynamic contrast enhanced (DCE) MRI. METHODS: Patients enrolled in a prospective pilot clinical trial received SABR for primary RCC, and had DWI and DCE MRI scheduled at baseline, 14 days and 70 days after SABR. Tumours <5cm diameter received a single fraction of 26 Gy and larger tumours received three fractions of 14 Gy...
2018: PloS One
Jae Hung Jung, Michael C Risk, Robert Goldfarb, Balaji Reddy, Bernadette Coles, Philipp Dahm
Cryotherapy is a minimally invasive treatment option of prostate cancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective this is in comparison to standard treatments such as radical prostatectomy and radiotherapy [1,2]. We updated a previously published Cochrane Review to assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localized (cT1-T2) or locally-advanced (cT3) non-metastatic prostate cancer by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries and a grey literature repository up to 6 March 2018 [3]...
August 16, 2018: BJU International
S Marnitz, C Köhler, N Gharbi, S Kunze, K Jablonska, J Herter
PURPOSE: For endometrial cancer (EC), clinical and pathological risk factors are taken to triage patients and estimate their prognosis. Lymph node involvement (pN+), lymphovascular space involvement (LSVI), grading, age of the patients, and T classification are internationally accepted parameters for treatment decisions. MATERIALS AND METHODS: Studies on adjuvant radiation, chemotherapy, and chemoradiation are discussed against the background of risk stratification and clinical decision-making in early-to-advanced stage endometrial cancer...
August 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Maria Tolia, Nikolaos Tsoukalas, Michail Nikolaou, Eftychia Mosa, Ioannis Nazos, Antigoni Poultsidi, Jiannis Hajiioannou, Konstantinos Tsanadis, Despoina Spyropoulou, Nikolaos Charalampakis, Dimitrios Kardamakis, Vasileios Kouloulias, Kyriaki Pistevou-Gombaki, George Kyrgias
Purpose: Several trials on noncancer population indicate that yoga is associated with meaningful clinical effects. This study evaluated the physical and psychosocial outcomes of yoga in oncologic patients treated with radiotherapy. Methods: We focused on a research through Cochrane Register of Controlled Trials (CENTRAL), BioMed Central, and MEDLINE studies up to May 2017. Results: Yoga was found to have a substantial benefit in cancer patients' distress, anxiety, and depression...
July 2018: Indian Journal of Palliative Care
Jingjing Wu, Lingling Duan, Lei Zhang, Zhenchang Sun, Xiaorui Fu, Xin Li, Ling Li, Xinhua Wang, Xudong Zhang, Zhaoming Li, Hui Yu, Yu Chang, Feifei Nan, Jiaqin Yan, Li Tian, Xiaoli Wang, Mingzhi Zhang
OBJECTIVE: This prospective, randomized, controlled and open-label clinical trial sought to evaluate the tolerability and efficacy of the FTD regimen (fotemustine, teniposide and dexamethasone) compared to HD-MA therapy (high-dose methotrexate plus cytarabine) and to elucidate some biomarkers that influence outcomes in patients with newly diagnosed primary CNS lymphoma. METHODS: Participants were stratified by IELSG risk score (low versus intermediate versus high) and randomly assigned (1:1) to receive four cycles of FTD or HD-MA regimen...
August 14, 2018: Journal of Neuro-oncology
Hongwei Li, Wei Chen, Jinbo Ma, Rukun Zang, Dong You, Sujing Liu, Cunqi Li, Yipeng Song
OBJECTIVES: Considering that adjuvant radiation therapy is one of the most common treatment methods and the influence of the clinical target volume to treatment-related toxicity, this study aimed to observe the differences in treatment failures about involved-field irradiation (IFI) without lymph node areas versus elective nodal irradiation (ENI) with lymph node areas in elderly patients with bladder cancer. MATERIAL AND METHODS: Ninety-two elderly bladder cancer patients were analyzed from January 2010 to December 2014 in one institution...
August 4, 2018: Current Problems in Cancer
Emma Maria Dunne, Ian Mark Fraser, Mitchell Liu
Stereotactic body radiation therapy (SBRT) also referred to as stereotactic ablative radiotherapy (SABR), is a technique which has emerged over the past two decades due to improvements in radiation technology. Unlike conventional external beam radiotherapy (cEBRT) which traditionally delivers radiation in small doses [approximately 2 Gray (Gy) per fraction] over several weeks, SBRT, typically delivered in one to eight fractions, is a technique whereby potentially ablative doses of radiotherapy (usually 7.5-20 Gy per fraction) can be delivered with steeper dose gradients and sub millimetre precision, minimising risk to surrounding normal tissues...
July 2018: Annals of Translational Medicine
Patricia Tai, Joseph Au
There are many different types of skin tumors in the World Health Organization (WHO) classification. The natural course and treatment varies according to the histological type. This review summarizes clinical experience for treatment decision. Contemporary radiotherapy and systemic therapy are improving. Landmark studies for basal cell and Merkel cell carcinomas (MCC) trigger further research and impetus for improving treatment outcome. Avelumab, nivolumab, pembrolizumab, ipilimumab appear to be promising for treatment of advanced MCCs and adjuvant trials are underway...
July 2018: Annals of Translational Medicine
Cedric M Panje, Konstantin J Dedes, Klazien Matter-Walstra, Matthias Schwenkglenks, Oliver Gautschi, Marco Siano, Daniel M Aebersold, Ludwig Plasswilm, Judith E Lupatsch
BACKGROUND: Novel systemic therapies have improved the prognosis of metastatic non-small cell lung cancer (NSCLC), but costs of some of these drugs are a matter of ongoing debate. More recently, local therapies (LT) such as radiotherapy and surgery have been suggested as additional treatment in oligometastatic NSCLC demonstrating an improved progression-free survival (PFS) in a phase II trial compared to maintenance chemotherapy (MC) alone. The aim of this analysis was to assess the cost-effectiveness of local therapies in oligometastatic NSCLC...
August 10, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Tomás Merino, Teresa Ip, Francisco Domínguez, Francisco Acevedo, Lidia Medina, Alejandra Villaroel, Mauricio Camus, Eugenio Vinés, César Sánchez
Background: Although fairly uncommon, loco-regional recurrence in breast cancer (BC) has major consequences for the patient. Several predictors for locoregional have been previously reported from large randomized clinical trials mainly from Europe & North America; data from other geographical areas are somewhat scarce. Here we performed a retrospective review of medical records in a single academic center in Chile, searching for predictors of breast tumor recurrence. Results: Median patient follow up was 61 months, 5 year overall survival (OS) rate was 94...
July 13, 2018: Oncotarget
Jordan A Holmes, Roger F Anderson, Leroy G Hoffman, Timothy N Showalter, Mohit Kasibhatla, Sean P Collins, Michael A Papagikos, Brittany D Barbosa, Lori J Stravers, Zahra Mahbooba, Andrew Z Wang, Ronald C Chen
BACKGROUND: Prostate cancer survivors who receive androgen deprivation therapy (ADT) are at increased risk of cardiovascular disease. They require coordinated care between cancer specialist and primary care physicians (PCPs) to monitor for cancer control and manage cardiovascular risk factors. METHODS: We prospectively enrolled 103 men receiving ADT with radiotherapy from 7 institutions to assess cardiovascular risk factors and survivorship care. Medical records, fasting labs, and patient-reported outcomes using a validated instrument were assessed at baseline (pre-treatment) and 1 year post-RT...
August 9, 2018: International Journal of Radiation Oncology, Biology, Physics
Taymeyah Al-Toubah, Jonathan Strosberg
Peptide receptor radionuclide therapy is a form of systemic radiotherapy shown to be effective in treating neuroendocrine tumors expressing somatostatin receptors. The NETTER-1 trial was the first randomized phase III clinical trial evaluating a radiolabeled somatostatin analog, and demonstrated significant improvement in progression-free survival among patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE versus high-dose octreotide. This article discusses the evolution of peptide receptor radionuclide therapy, side effects, and potential future treatment approaches...
September 2018: Endocrinology and Metabolism Clinics of North America
J Kobiela, P Spychalski, G Marvaso, D Ciardo, V Dell'Acqua, F Kraja, A Błażyńska-Spychalska, A J Łachiński, A Surgo, R Glynne-Jones, B A Jereczek-Fossa
BACKGROUND: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. MATERIALS AND METHODS: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included...
September 2018: Critical Reviews in Oncology/hematology
Consuelo Buttigliero, Simona Allis, Marcello Tucci, Clizia Zichi, Gianmarco Leone, Rosario Francesco Di Stefano, Maria Grazia Ruo Redda, Umberto Ricardi, Giorgio Vittorio Scagliotti, Massimo Di Maio, Andrea Riccardo Filippi
In the last few years, immune checkpoint inhibitors have been extensively investigated in renal cell carcinoma and led to remarkable results. Radiation therapy may increase the activity of immune modulating agents through different mechanisms, priming the immune system, recruiting immune cells to the tumor environment, and altering the immunosuppressive effects of the tumor microenvironment. Preclinical studies reported increased loco-regional control when radiation is combined with immune-checkpoint blockade...
July 20, 2018: Cancer Treatment Reviews
Christian Gisselbrecht, David Sibon
PURPOSE OF REVIEW: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell and natural killer (NK)-cell neoplasms in the WHO 2016 classification. Patient prognosis is poor when treated with CHOP, and there is an unmet need for new drugs. Several agents have been developed for PTCL, and their use is the subject of this review. RECENT FINDINGS: Phase 2 studies demonstrated the activity of new drugs in Relapsed/refractory PTCL. Only four compounds were approved by the food and drug administration: romidepsin and belinostat, which are epigenetic modifiers, the antifolate agent pralatrexate, the immuno-conjugate brentuximab vedotin...
September 2018: Current Opinion in Oncology
John A Vargo, Kristie M Sparks, Rahul Singh, Geraldine M Jacobson, Joshua D Hack, Christopher P Cifarelli
BACKGROUND AND PURPOSE: Post-operative SRS (stereotactic radiosurgery) for large brain metastases is challenged by risks of radiation necrosis that limit SRS dose. Intraoperative radiotherapy (IORT) is a potential alternative, however standard dose recommendations are lacking. METHODS AND MATERIALS: Twenty consecutive brain metastases treated with post-operative SRS were retrospectively compared to IORT plans generated for 10-30 Gy in 1 fraction to 0-5 mm by estimating the applicator size and distance from critical organs using pre-operative and post-operative MRI...
August 9, 2018: Journal of Neuro-oncology
Agata Karklelyte, Konstantinas Povilas Valuckas, Romas Griskevicius, Ernestas Janulionis, Eduardas Aleknavicius
Purpose: The aim of our study was to perform the final analysis of acute toxicity and quality of life data obtained from 221 consecutive patients who suffered from intermediate-to-high risk prostate cancer. Methods: In this trial, 221 patients were randomized to receive either hypofractionated (63 Gy in 20 fractions, 4 fractions/week) or conventionally fractionated (76 Gy in 38 fractions, 5 fractions/week) radiotherapy to the prostate and seminal vesicles. Elective pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially and 44 Gy in 20 fractions simultaneously was also applied...
July 2018: Reports of Practical Oncology and Radiotherapy
Wolfgang Wick, Matthias Osswald, Antje Wick, Frank Winkler
The diagnosis of a glioblastoma is mainly made on the basis of their microscopic appearance with the additional determination of epigenetic as well as mutational analyses as deemed appropriate and taken into account in different centers. How far the recent discovery of tumor networks will stimulate novel treatments is a subject of intensive research. A tissue diagnosis is the mainstay. Regardless of age, patients should undergo a maximal safe resection. Magnetic resonance imaging is the surrogate parameter of choice for follow up...
2018: Therapeutic Advances in Neurological Disorders
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"